Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65)

Journal of Virology

Volumn 75, Issue 14, 2001, Pages 6584-6600

  Holtappels, R ^a   Podlech, J ^a   Grzimek, N K A ^a   Thomas, D ^a   Pahl Seibert, M F ^a   Reddehase, M J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PROTEIN PM84; PROTEIN PP65; PROTEIN PPM83; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL SPECIFICITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; T LYMPHOCYTE; VIRION; VIRUS REPLICATION;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; HERPESVIRIDAE INFECTIONS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MUROMEGALOVIRUS; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; VIRAL MATRIX PROTEINS;

EID: 0034984520     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.14.6584-6600.2001     Document Type: Article

References (68)

1. Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells
2. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes
3. + T-cell response is much less apparent following secondary challenge
4. + T cells during viral persistence in the central nervous system
5. Recognition of human cytomegalovirus (HCMV) gene products by HCMV-specific cytotoxic T cells
6. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate-early protein and glycoprotein B expressed by recombinant vaccinia viruses
7. A subset of viral transcripts packaged within human cytomegalovirus particles
8. Nonviral microbodies with viral antigenicity produced in cytomegalovirus-infected cells
9. Identification, analysis, and evolutionary relationships of the putative murine cytomegalovirus homologs of the human cytomegalovirus UL82 (pp71) and UL83 (pp65) matrix phosphoproteins
10. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope
11. Normal and pathologic anatomy of the adrenal gland of the mouse, including neoplasms
12. Protective cellular immunity: Cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization
13. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides
14. + T lymphocytes in healthy seropositive donors
15. DNA immunization confers protection against murine cytomegalovirus infection
16. Ultrastructural analysis of circulating cytomegalic cells in patients with active cytomegalovirus infection: Evidence for virus production and endothelial origin
17. In vivo replication of recombinant murine cytomegalovirus driven by the paralogous major immediate-early promoter-enhancer of human cytomegalovirus
18. Immune evasion by cytomegalovirus - Survival strategies of a highly adapted opportunist
19. lo memory-effector cell pool during latent murine cytomegalovirus infection of the lungs
20. Control of murine cytomegalovirus in the lungs: Relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates
21. The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells
22. d-restricted antigenic peptide encoded by murine cytomegalovirus early gene M84
23. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20S proteasome
24. A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates
25. Isolation and characterization of a non-infectious virion-like particle released from cells infected with human strains of cytomegalovirus
26. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection
27. T-cell epitope mapping by flow cytometry
28. Multiplicity dependent expression of the predominant phosphoprotein pp65 of human cytomegalovirus
29. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class 1 MHC molecules in the ER which is not retained bur is transported to the cell surface
30. Principles of cytomegalovirus antigen presentation in vitro and in vivo
31. Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes
32. Latency versus persistence or intermittent recurrences: Evidence for a latent state of murine cytomegalovirus in the lungs
33. Identification of a monoclonal antibody specific for a murine T3 polypeptide
34. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes
35. In vivo replication, latency, and immunogenicity of murine cytomegalovirus mutants with deletions in the M83 and M84 genes, the putative homologs of human cytomegalovirus pp65 (UL83)
36. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65)
37. Protection against lethal viral infection by vaccination with nonimmunodominant peptides
38. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression
39. Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: Persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection
40. Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation
41. Analysis of the complete DNA sequence of murine cytomegalovirus
42. The immunogenicity of human and murine cytomegaloviruses
43. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease
44. Cloned long-term cytolytic T-lymphocyte line with specificity for an immediate-early membrane antigen of murine cytomegalovirus
45. Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors
46. The cytolytic T lymphocyte response to the murine cytomegalovirus. I. Distinct maturation stages of cytolytic T lymphocytes constitute the cellular immune response during acute infection of mice with the murine cytomegalovirus
47. The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors
48. Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection
49. In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection
50. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes
51. Interstitial murine cytomegalovirus pneumonia after irradiation: Characterization of cells that limit viral replication during established infection of the lungs
52. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
53. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression
54. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
55. Human cytomegalovirus and dense bodies: Glycopeptide analysis and mechanism of cell rounding and polykaryocytosis
56. The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for gowth in cell culture
57. Preemptive CD8-T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genome, and reduces the risk of virus recurrence
58. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay
59. The selectins: Vascular adhesion molecules
60. Hyperimmediate entry of human cytomegalovirus virions and dense bodies into human fibroblasts
61. Analysis of cytotoxic T cell responses to dominant and sub-dominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection
62. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
63. Studies on the morphogenesis of murine cytomegalovirus
64. Cytomegaloviruses use multiple mechanisms to elude the host immune response
65. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL
66. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses